Cancer detection that's as determined as you are.

While grappling with your child’s cancer journey can be scary and challenging, pediatric treatments for acute lymphoblastic leukemia (ALL) have come a long way in recent years. Your child deserves advanced tools that can detect even the smallest traces of disease. This information can be critical to making important decisions about your child’s care.1-3

clonoSEQ® (pronounced clo-no-seek) is an advanced test that measures the small number of cancer cells that may remain in your child’s body during and after treatment. This is called measurable (or minimal) residual disease, also known as MRD.1

Learn about MRD

Often, MRD doesn’t cause any signs or symptoms, but its presence may be a signal that cancer is returning.1

When it comes to treating pediatric ALL, your child’s doctor’s ability to detect and monitor these traces of disease may be important for making timely and informed decisions about their treatment plan.2,3

Learn more about MRD

See how clonoSEQ can inform your child’s care

clonoSEQ can help you and your child’s doctor make informed decisions throughout their cancer journey.

MRD testing helps you and your child’s doctor assess their response to treatment, measure their disease over time, and potentially detect early signs of returning cancer by assessing low levels of disease other tests may miss.1-3

Learn more about clonoSEQ

Understand your child’s coverage and support options

Medicare and other major insurance providers cover clonoSEQ testing performed on blood and bone marrow samples from patients with multiple myeloma, DLBCL, CLL, ALL or MCL at multiple time points throughout treatment.

Adaptive Assist™ is our patient support program that’s tailored to your family’s individual needs..

See how we can help

“The results of this test gave me my life back.”

— Karen, blood cancer patient
Hear from a real patient

This page is intended for a US-based audience.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory-developed test (LDT). To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.

References:

  1. clonoSEQ®. [technical summary]. Seattle, WA. Adaptive Biotechnologies; 2020.
  2. Pulsipher M, et al. Blood. 2015;125(22):3501-3508.
  1. Wood B, et al. Blood. 2018;131(12):1350-1359.